Amneal Pharmaceuticals, Inc. (AMRX)

Acerca de Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Al 3 de noviembre de 2026, la acción de Amneal Pharmaceuticals, Inc. (AMRX) bajó a $20.20, una baja de 1.17% (-$0.24) frente al cierre anterior. En la sesión, las acciones han operado entre $19.68 y $20.80. Eso ubica a AMRX en el tercio superior de su rango de 52 semanas, de $10.92 a $21.68. Amneal Pharmaceuticals, Inc. opera en el sector de pharmaceutical preparations y tiene una capitalización de mercado de aproximadamente $7.12 mil millones, con cerca de 914.1 mil acciones negociadas.

Últimas noticias de AMRX

• NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales ViewYahoo Finance· 3 nov, 10:15 a.m. ET
• JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales ViewYahoo Finance· 3 nov, 10:12 a.m. ET
• Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone RevenuesYahoo Finance· 3 nov, 9:59 a.m. ET
• CRSP's Q3 Loss Wider Than Expected, Sales Beat EstimatesYahoo Finance· 3 nov, 9:24 a.m. ET
• Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to SayYahoo Finance· 3 nov, 8:30 a.m. ET
• Amneal (NASDAQ:AMRX) beats expectations in strong Q3 2026, full-year outlook slightly exceeds expectationsYahoo Finance· 3 nov, 6:30 a.m. ET
• Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top EstimatesYahoo Finance· 3 nov, 6:25 a.m. ET
• Amneal Reports Third Quarter 2026 Financial ResultsYahoo Finance· 3 nov, 6:00 a.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de AMRX en un solo lugar? Crea una cuenta gratis →

• https://www.marketbeat.com/earnings/reports/2026-11-3-amneal-pharmaceuticals-inc-stock-1/ $AMRX Amneal Pharmaceuticals Earnings Transcript

  @EarningsInsider· 3 nov, 10:03 a.m. ET

• $AMRX reported earnings this morning before the open and beat EPS estimates: $0.26 adjusted EPS vs $0.2374 expected, according to Stock Meadow.

  @shoc24· 3 nov, 9:28 a.m. ET· Alcista

• $AMRX Q3 '26 Earnings Results & Recap Amneal increased full year 2026 net revenue guidance to $3.15B$3.25B, adjusted EBITDA to $800M$815M, and adjusted diluted EPS to $1.04$1.08; operating cash flow guidance was updated to $325M$375M.

  @StocktwitsEarnings· 3 nov, 7:45 a.m. ET

• $AMRX $LLY $REGN GLP-1 medications are the single largest driver of Lilly's explosive financial growth.$QQQ

  @inspector_gadget86· 30 oct, 8:24 p.m. ET· Alcista

• $AMRX $LLY $REGN exceptionally strong third-quarter earnings report driven by blockbuster demand for its GLP-1 medications.

  @inspector_gadget86· 30 oct, 8:23 p.m. ET· Alcista

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →